Improving Lives Through Nuclear Medicine™


Heart Disease

Heart disease is the leading cause of death worldwide and its prevalence is growing. It is estimated that by 2030, 44% of the US population is projected to have some form of cardiovascular disease, which encompasses heart conditions and stroke. Over the same time period, the total direct medical costs are expected to nearly triple.1

Physicians may perform nuclear medicine tests—such as myocardial perfusion imaging—to diagnose heart disease and monitor a patient’s progress over time.

Advancing Nuclear Medicine in the Diagnosis of Heart Disease

Jubilant Radiopharma is committed to developing products and technologies that enable physicians to optimize the diagnosis and risk stratification of patients with heart disease. Jubilant Radiopharma is making significant investments in nuclear cardiology to help realize its promise for healthcare professionals, patients, and the entire healthcare system.

Myocardial Perfusion Imaging

About MPI

Nuclear cardiology diagnostic studies play an important role in the non-invasive evaluation of cardiac physiology and function including myocardial perfusion. The use of nuclear cardiovascular examinations permits the sensitive detection and diagnosis of numerous cardiac abnormalities as well as the determination of the functional consequences and prognosis of coronary artery disease.

Imaging of myocardial perfusion with radiopharmaceuticals is the most commonly performed cardiac examination in nuclear medicine practice. Its primary goal is to determine the adequacy of blood flow to the myocardium, especially in conjunction with exercise or pharmacologic stress for the detection, localization and evaluation of coronary artery disease (CAD).

Clinical Resources

The following resources are available for healthcare professionals who diagnose and treat patients with heart disease:

  • ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. View PDF.
  • American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging joint position statement on the clinical indications for myocardial perfusion PET. View PDF.


1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-322.


This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. For full Prescribing Information including indications, contraindications, warnings, precautions and adverse events, please see the appropriate product labeling.


We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.